These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38656662)

  • 1. Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study.
    Coratti G; Bovis F; Pera MC; Scoto M; Montes J; Pasternak A; Mayhew A; Muni-Lofra R; Duong T; Rohwer A; Dunaway Young S; Civitello M; Salmin F; Mizzoni I; Morando S; Pane M; Albamonte E; D'Amico A; Brolatti N; Sframeli M; Marini-Bettolo C; Sansone VA; Bruno C; Messina S; Bertini E; Baranello G; Day J; Darras BT; De Vivo DC; Hirano M; Muntoni F; Finkel R; Mercuri E;
    Eur J Neurol; 2024 Aug; 31(8):e16309. PubMed ID: 38656662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy.
    Stolte B; Bois JM; Bolz S; Kizina K; Totzeck A; Schlag M; Kleinschnitz C; Hagenacker T
    Eur J Neurol; 2020 Dec; 27(12):2586-2594. PubMed ID: 32781490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3.
    Wolfe A; Stimpson G; Ramsey D; Coratti G; Dunaway Young S; Mayhew A; Pane M; Rohwer A; Muni Lofra R; Duong T; O'Reilly E; Milev E; Civitello M; Sansone VA; D'Amico A; Bertini E; Messina S; Bruno C; Albamonte E; Mazzone E; Main M; Montes J; Glanzman AM; Zolkipli-Cunningham Z; Pasternak A; Marini-Bettolo C; Day JW; Darras BT; De Vivo DC; Baranello G; Scoto M; Finkel RS; Mercuri E; Muntoni F;
    J Neuromuscul Dis; 2024; 11(3):665-677. PubMed ID: 38427497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug treatment for spinal muscular atrophy types II and III.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients.
    O'Hagen JM; Glanzman AM; McDermott MP; Ryan PA; Flickinger J; Quigley J; Riley S; Sanborn E; Irvine C; Martens WB; Annis C; Tawil R; Oskoui M; Darras BT; Finkel RS; De Vivo DC
    Neuromuscul Disord; 2007 Oct; 17(9-10):693-7. PubMed ID: 17658255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4.
    Wadman RI; Wijngaarde CA; Stam M; Bartels B; Otto LAM; Lemmink HH; Schoenmakers MAGC; Cuppen I; van den Berg LH; van der Pol WL
    Eur J Neurol; 2018 Mar; 25(3):512-518. PubMed ID: 29194869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age and baseline values predict 12 and 24-month functional changes in type 2 SMA.
    Coratti G; Pera MC; Lucibello S; Montes J; Pasternak A; Mayhew A; Glanzman AM; Young SD; Pane M; Scoto M; Messina S; Goemans N; Osorio AN; Pedemonte M; Sansone V; Bertini E; De Vivo DC; Finkel R; Muntoni F; Mercuri E;
    Neuromuscul Disord; 2020 Sep; 30(9):756-764. PubMed ID: 32900576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Old measures and new scores in spinal muscular atrophy patients.
    Mazzone E; Montes J; Main M; Mayhew A; Ramsey D; Glanzman AM; Dunaway S; Salazar R; Pasternak A; Quigley J; Pane M; Pera MC; Scoto M; Messina S; Sframeli M; D'amico A; Van Den Hauwe M; Sivo S; Goemans N; Darras BT; Kaufmann P; Bertini E; De Vivo DC; Muntoni F; Finkel R; Mercuri E
    Muscle Nerve; 2015 Sep; 52(3):435-7. PubMed ID: 26111847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum leptin levels in children and adolescents with spinal muscular atrophy types 2 and 3
    Djordjevic S; Milic-Rasic V; Brankovic V; Kosac A; Dejanovic-Djordjevic I; Bijelic M; Dimkic-Tomic T; Markovic-Denic L; Kovacevic S; Petrovic H; Vitorovic S; Dobric Z; Zdravkovic V
    Arch Pediatr; 2022 Oct; 29(7):480-483. PubMed ID: 36109285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gain and loss of abilities in type II SMA: A 12-month natural history study.
    Coratti G; Lucibello S; Pera MC; Duong T; Muni Lofra R; Civitello M; D'Amico A; Goemans N; Darras BT; Bruno C; Sansone VA; Day J; Nascimento Osorio A; Muntoni F; Montes J; Sframeli M; Finkel R; Mercuri E;
    Neuromuscul Disord; 2020 Sep; 30(9):765-771. PubMed ID: 32893082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool.
    Ramsey D; Scoto M; Mayhew A; Main M; Mazzone ES; Montes J; de Sanctis R; Dunaway Young S; Salazar R; Glanzman AM; Pasternak A; Quigley J; Mirek E; Duong T; Gee R; Civitello M; Tennekoon G; Pane M; Pera MC; Bushby K; Day J; Darras BT; De Vivo D; Finkel R; Mercuri E; Muntoni F
    PLoS One; 2017; 12(2):e0172346. PubMed ID: 28222119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responsiveness of the motor function measure in patients with spinal muscular atrophy.
    Vuillerot C; Payan C; Iwaz J; Ecochard R; Bérard C;
    Arch Phys Med Rehabil; 2013 Aug; 94(8):1555-61. PubMed ID: 23380348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nusinersen for adults with spinal muscular atrophy.
    Arslan D; Inan B; Kilinc M; Bekircan-Kurt CE; Erdem-Ozdamar S; Tan E
    Neurol Sci; 2023 Jul; 44(7):2393-2400. PubMed ID: 36854931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physical exercise training for type 3 spinal muscular atrophy.
    Bartels B; Montes J; van der Pol WL; de Groot JF
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012120. PubMed ID: 30821348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy.
    Pera MC; Coratti G; Forcina N; Mazzone ES; Scoto M; Montes J; Pasternak A; Mayhew A; Messina S; Sframeli M; Main M; Lofra RM; Duong T; Ramsey D; Dunaway S; Salazar R; Fanelli L; Civitello M; de Sanctis R; Antonaci L; Lapenta L; Lucibello S; Pane M; Day J; Darras BT; De Vivo DC; Muntoni F; Finkel R; Mercuri E
    BMC Neurol; 2017 Feb; 17(1):39. PubMed ID: 28231823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Executive function is inversely correlated with physical function: the cognitive profile of adult Spinal Muscular Atrophy (SMA).
    Mix L; Schreiber-Katz O; Wurster CD; Uzelac Z; Platen S; Gipperich C; Ranxha G; Wieselmann G; Osmanovic A; Ludolph AC; Petri S; Lulé D
    Orphanet J Rare Dis; 2021 Jan; 16(1):10. PubMed ID: 33407722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year.
    Kaufmann P; McDermott MP; Darras BT; Finkel R; Kang P; Oskoui M; Constantinescu A; Sproule DM; Foley AR; Yang M; Tawil R; Chung W; Martens B; Montes J; O'Hagen J; Dunaway S; Flickinger JM; Quigley J; Riley S; Glanzman AM; Benton M; Ryan PA; Irvine C; Annis CL; Butler H; Caracciolo J; Montgomery M; Marra J; Koo B; De Vivo DC; ;
    Arch Neurol; 2011 Jun; 68(6):779-86. PubMed ID: 21320981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spinal muscular atrophy: survival pattern and functional status.
    Chung BH; Wong VC; Ip P
    Pediatrics; 2004 Nov; 114(5):e548-53. PubMed ID: 15492357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Variability in Spinal Muscular Atrophy Type III.
    Coratti G; Messina S; Lucibello S; Pera MC; Montes J; Pasternak A; Bovis F; Exposito Escudero J; Mazzone ES; Mayhew A; Glanzman AM; Young SD; Salazar R; Duong T; Muni Lofra R; De Sanctis R; Carnicella S; Milev E; Civitello M; Pane M; Scoto M; Bettolo CM; Antonaci L; Frongia A; Sframeli M; Vita GL; D'Amico A; Van Den Hauwe M; Albamonte E; Goemans N; Darras BT; Bertini E; Sansone V; Day J; Nascimento Osorio A; Bruno C; Muntoni F; De Vivo DC; Finkel RS; Mercuri E
    Ann Neurol; 2020 Dec; 88(6):1109-1117. PubMed ID: 32926458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience.
    Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL
    Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.